ABSTRACT
AIMS: Investigation of antimicrobial activity and phytochemicals of Alpinia malaccensis (Ran-kiriya) against foodborne bacteria Staphyloccocus aureus, Listeria monocytogenes, Escherichia coli and Salmonella Typhimurium. METHODS AND RESULTS: Antibacterial activity was tested on the above four foodborne bacteria using agar disc diffusion and broth dilution assay. Alpinia malaccensis rhizome extract chemical composition was determined using gas chromatography-mass spectrometry (GCMS). Active compound was identified using thin-layer chromatography (TLC) and confirmed by nuclear magnetic resonance spectroscopy (NMR). The A. malaccensis rhizome hexane crude extract showed significantly (P < 0·05) higher diameter of inhibition (DIZ) 40 ± 0·52, 38 ± 0·96 and 36 ± 1·45 mm for S. aureusSA113, MSSASS25D and methicillin-resistant S. aureus compared with other tested bacteria. The minimum inhibition concentration and minimum bactericidal concentration were 0·625 and 5 mg ml-1 for S. aureus 113. TLC showed DIZ 39 ± 0·12 mm only for one fraction. The crude extract showed 82·87% a major compound by GCMS which is the active fraction. This purified active fraction was confirmed as 1'acetoxychavicol acetate (1'ACA) by NMR. No significantly different inhibition was observed for crude extract and purified compound. CONCLUSIONS: Bioactive 1'ACA of A. malaccensis showed strong antibacterial activity against S. aureus strains including MRSA strain. SIGNIFICANCE AND IMPACT OF THE STUDY: This study is the first to identify 1'ACA from A. malaccensis. The crude or purified compound could potentially be developed as antimicrobials.
Subject(s)
Alpinia/chemistry , Anti-Bacterial Agents , Food Microbiology , Phytochemicals , Plant Extracts , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacology , Bacteria/drug effects , Phytochemicals/chemistry , Phytochemicals/pharmacology , Plant Extracts/chemistry , Plant Extracts/pharmacologyABSTRACT
Coconut, Cocos nucifera L., is a tree that is cultivated to provide a large number of products, although it is mainly grown for its nutritional and medicinal values. Coconut oil, derived from the coconut fruit, has been recognised historically as containing high levels of saturated fat; however, closer scrutiny suggests that coconut should be regarded more favourably. Unlike most other dietary fats that are high in long-chain fatty acids, coconut oil comprises medium-chain fatty acids (MCFA). MCFA are unique in that they are easily absorbed and metabolised by the liver, and can be converted to ketones. Ketone bodies are an important alternative energy source in the brain, and may be beneficial to people developing or already with memory impairment, as in Alzheimer's disease (AD). Coconut is classified as a highly nutritious 'functional food'. It is rich in dietary fibre, vitamins and minerals; however, notably, evidence is mounting to support the concept that coconut may be beneficial in the treatment of obesity, dyslipidaemia, elevated LDL, insulin resistance and hypertension - these are the risk factors for CVD and type 2 diabetes, and also for AD. In addition, phenolic compounds and hormones (cytokinins) found in coconut may assist in preventing the aggregation of amyloid-ß peptide, potentially inhibiting a key step in the pathogenesis of AD. The purpose of the present review was to explore the literature related to coconut, outlining the known mechanistic physiology, and to discuss the potential role of coconut supplementation as a therapeutic option in the prevention and management of AD.
